Immunotherapy injections inhibiting PD-1 receptors, distributed by biotech suppliers to specialized cancer treatment facilities. Utilized by oncologists in hospitals for managing melanoma, lung, and head-neck cancers through intravenous delivery in outpatient and inpatient oncology protocols.